Evaluating Pembrolizumab, Bevacizumab, and Oral Metronomic Cyclophosphamide in Heavily Pretreated Platinum-Resistant Ovarian Cancer: Real-World Outcomes and Clinical Implications
Posted innews OB/GYN & Women's Health Oncology

Evaluating Pembrolizumab, Bevacizumab, and Oral Metronomic Cyclophosphamide in Heavily Pretreated Platinum-Resistant Ovarian Cancer: Real-World Outcomes and Clinical Implications

This study assesses the efficacy and safety of pembrolizumab combined with bevacizumab and oral metronomic cyclophosphamide in heavily pretreated platinum-resistant ovarian cancer patients, showing modest disease control with manageable toxicity in a real-world setting.